Papillary thyroid cancer (PTC) is the most common pathological type of thyroid cancer
always with favorable prognosis. However
the incidence of thyroid cancer recently appeared to be an increasing trend. Because of the increased amount of patients
refractory thyroid cancer was not rare anymore. Hence
we are facing a big challenge how to manage and treat the increasing number of patients. BRAF V600E mutation is a classic DNA-relative biomarker for PTC
and widely used in preoperative diagnosis and evaluation of prognosis. As a potential therapeutic target
it attracted more and more attention. Recognizing BRAF V600E mutation can help us to know oncogenesis and biological behavior of PTC better and provide profitable treatment and management.